The flavonoid 2nitroflavone suppresses human triple-negative breast cancer cell growth in vitro.

VACHETTA, VANINA; FERRAGUT, FÁTIMA; CARABIAS, PABLO; MARDER, MARIEL; ELOLA, MARÍA TERESA; TRONCOSO, MARÍA F.

CABA

Congreso; Reunión Conjunta de Sociedades de Biociencias - LXII Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica. Ciudad Autónoma de Buenos Aires.; 2017

SOCIEDAD ARGENTINA DE INVESTIGACION CLINICA

The flavonoid 2?nitroflavone suppresses human triple-negative breast cancer cell growth in vitroVachetta VS, Ferragut F, Carabias P, Marder M, Elola MT, Troncoso MF IQUIFIB, Facultad de Farmacia y Bioquímica, UBA. In addition to the human epidermal growth factor receptor 2 (HER2)-positive subtype,triple-negative breast cancer (TNBC) is one the most aggressive subtype of mammary tumor. Owing to its lack of estrogen receptor, progesterone receptor and HER2, neither endocrine nor anti-HER2 molecular targeting therapy yield promising results, and standard chemotherapy is the backbone of systemic treatment. Flavonoids are a group of polyphenolic compounds considered potential chemopreventive candidates for cancer treatment. Previously, we synthesized the flavonoid 2?nitroflavone (2?NF) and it was demonstrated to induce LM3 murine mammary adenocarcinoma cell apoptosis and to act as an anti-tumor agent in vivo. Our aim was to evaluate 2?NF effect on human TNBC cell growth invitro. 2?NF exerted a dose- and time-dependent inhibitory effect on MDA-MB-231 and MDA-MB-468 cells (MTT assay). The half maximal inhibitory concentration (IC50) was 3.13±0.39 and 6.97±1.37% µM at 72h for MDA-MB-231 and MDA-MB-468 cells, respectively. Maximal inhibition of MDA-MB-231 cell growth (66.27±5.24%, vehicle control: 100% p